Otros idiomas FibroGen, Inc.

Acciones

FGEN

US31572Q8087

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 02/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1,13 ^USD	-3,42 %		+10,78 %	+27,50 %

24/04	FibroGen, Inc. presentará datos clínicos del estudio de fase 1B de escalada de dosis de FG-3246 (FOR46) en combinación con enzalutamida en pacientes con cáncer de próstata metastásico resistente a la castración en la Reunión Anual de 2024 de la Sociedad Americana de Oncología Clínica	CI
15/04	Faron Pharmaceuticals vuelve a nombrar al antiguo jefe de finanzas de forma interina	AN

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

FibroGen to Report First Quarter 2024 Financial Results	29/04
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting	24/04
FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting	24/04
Faron Pharmaceuticals reappoints former finance chief on interim basis	15/04
Top Midday Decliners	03/04
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise	03/04
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	02/04
Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	02/04
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference	26/03
FibroGen : Corporate Presentation – March 2024	19/03
Sector Update: Health Care Stocks Rise Late Afternoon	12/03
Sector Update: Health Care Stocks Higher in Afternoon Trading	12/03
FibroGen Shares Jump After CEO Stock Purchase	12/03
FibroGen Names Deyaa Adib Chief Medical Officer	11/03
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer	11/03
FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer	11/03
FibroGen : Corporate Presentation – March 2024	06/03
FibroGen: Q4 Earnings Snapshot	26/02
FibroGen regains rights to anemia drug from AstraZeneca	26/02
FibroGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas FibroGen, Inc.

Acciones

FGEN

US31572Q8087

Otros idiomas

Filtros